Junyun Lai

2.1k total citations · 1 hit paper
16 papers, 1.2k citations indexed

About

Junyun Lai is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Junyun Lai has authored 16 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in Junyun Lai's work include Immune Cell Function and Interaction (8 papers), CAR-T cell therapy research (7 papers) and Immunotherapy and Immune Responses (5 papers). Junyun Lai is often cited by papers focused on Immune Cell Function and Interaction (8 papers), CAR-T cell therapy research (7 papers) and Immunotherapy and Immune Responses (5 papers). Junyun Lai collaborates with scholars based in Australia, Singapore and United States. Junyun Lai's co-authors include Paul A. Beavis, Phillip K. Darcy, Imran G. House, Sherly Mardiana, Kevin Sek, Emma V. Petley, Melissa A. Henderson, Lauren Giuffrida, Kirsten L. Todd and Amanda X. Y. Chen and has published in prestigious journals such as Nature Communications, Blood and Immunity.

In The Last Decade

Junyun Lai

15 papers receiving 1.2k citations

Hit Papers

Macrophage-Derived CXCL9 and CXCL10 Are Required for Anti... 2019 2026 2021 2023 2019 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Junyun Lai Australia 13 819 697 336 182 137 16 1.2k
Kevin Sek Australia 8 935 1.1× 749 1.1× 419 1.2× 205 1.1× 159 1.2× 11 1.3k
Imran G. House Australia 12 700 0.9× 642 0.9× 306 0.9× 127 0.7× 117 0.9× 14 1.1k
Marie-Andrée Forget United States 11 748 0.9× 500 0.7× 263 0.8× 129 0.7× 150 1.1× 12 947
Melissa A. Henderson Australia 12 1.1k 1.3× 818 1.2× 450 1.3× 230 1.3× 182 1.3× 17 1.5k
Bianca von Scheidt Australia 16 918 1.1× 938 1.3× 215 0.6× 140 0.8× 103 0.8× 21 1.3k
Kristen Fousek United States 11 703 0.9× 431 0.6× 298 0.9× 198 1.1× 122 0.9× 21 1.1k
Amanda X. Y. Chen Australia 6 607 0.7× 507 0.7× 260 0.8× 119 0.7× 106 0.8× 6 853
Emma V. Petley Australia 5 624 0.8× 511 0.7× 237 0.7× 121 0.7× 101 0.7× 7 854
Sherly Mardiana Australia 12 1.2k 1.4× 824 1.2× 444 1.3× 306 1.7× 256 1.9× 13 1.5k
Kirsten L. Todd Australia 5 585 0.7× 475 0.7× 230 0.7× 118 0.6× 97 0.7× 5 800

Countries citing papers authored by Junyun Lai

Since Specialization
Citations

This map shows the geographic impact of Junyun Lai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junyun Lai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junyun Lai more than expected).

Fields of papers citing papers by Junyun Lai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junyun Lai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junyun Lai. The network helps show where Junyun Lai may publish in the future.

Co-authorship network of co-authors of Junyun Lai

This figure shows the co-authorship network connecting the top 25 collaborators of Junyun Lai. A scholar is included among the top collaborators of Junyun Lai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junyun Lai. Junyun Lai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Beavis, Paul A., Junyun Lai, Gordon G. Wallace, et al.. (2025). Implantable drug delivery system improves tolerability of anti-CD40/anti-PD1 and chemotherapy in a murine model of breast cancer. European Journal of Pharmaceutical Sciences. 216. 107359–107359.
2.
Evrard, Maximilien, Étienne Becht, Raíssa Fonseca, et al.. (2023). Single-cell protein expression profiling resolves circulating and resident memory T cell diversity across tissues and infection contexts. Immunity. 56(7). 1664–1680.e9. 38 indexed citations
3.
Wu, Ling, Joanna Brzostek, Qianru Wei, et al.. (2023). CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance. Cell Reports Medicine. 4(2). 100917–100917. 22 indexed citations
4.
Chan, Jack D., Junyun Lai, Clare Y. Slaney, et al.. (2021). Cellular networks controlling T cell persistence in adoptive cell therapy. Nature reviews. Immunology. 21(12). 769–784. 155 indexed citations
5.
Giuffrida, Lauren, Kevin Sek, Melissa A. Henderson, et al.. (2021). CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nature Communications. 12(1). 3236–3236. 150 indexed citations
6.
Yu, F., Nicholas Syn, Yanan Lu, et al.. (2021). Characterization and Establishment of a Novel EBV Strain Simultaneously Associated With Nasopharyngeal Carcinoma and B-Cell Lymphoma. Frontiers in Oncology. 11. 626659–626659. 2 indexed citations
7.
Wu, Ling, Joanna Brzostek, Shvetha Sankaran, et al.. (2021). Targeting CAR to the Peptide-MHC Complex Reveals Distinct Signaling Compared to That of TCR in a Jurkat T Cell Model. Cancers. 13(4). 867–867. 12 indexed citations
8.
Giuffrida, Lauren, Kevin Sek, Melissa A. Henderson, et al.. (2020). IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. Molecular Therapy. 28(11). 2379–2393. 74 indexed citations
9.
Lai, Junyun, Sherly Mardiana, Imran G. House, et al.. (2020). Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nature Immunology. 21(8). 914–926. 159 indexed citations
10.
House, Imran G., Peter Savas, Junyun Lai, et al.. (2019). Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clinical Cancer Research. 26(2). 487–504. 412 indexed citations breakdown →
11.
Mardiana, Sherly, Junyun Lai, Imran G. House, Paul A. Beavis, & Phillip K. Darcy. (2019). Switching on the green light for chimeric antigen receptor T‐cell therapy. Clinical & Translational Immunology. 8(5). e1046–e1046. 11 indexed citations
12.
Beavis, Paul A., Melissa A. Henderson, Lauren Giuffrida, et al.. (2018). Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3− Cell–Mediated Modulation of CD103+ Dendritic Cells. Cancer Immunology Research. 6(9). 1069–1081. 51 indexed citations
14.
Lai, Junyun, Angeline Lim, Youjia Zhong, et al.. (2016). Targeting Epstein-Barr virus–transformed B lymphoblastoid cells using antibodies with T-cell receptor–like specificities. Blood. 128(10). 1396–1407. 17 indexed citations
15.
Oo, Min Zin, Junyun Lai, Shu Uin Gan, et al.. (2013). Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodies. Scientific Reports. 3(1). 3232–3232. 18 indexed citations
16.
Khor, Hwei Ling, Ottavio Beretta, Junyun Lai, et al.. (2013). The NLRP3 inflammasome affects DNA damage responses after oxidative and genotoxic stress in dendritic cells. European Journal of Immunology. 43(8). 2126–2137. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026